Clinical Trial: suPAR Michigan M2C2 Heterogeneity Cohort Study

U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07466524) titled 'suPAR Michigan M2C2 Heterogeneity Cohort Study' on Feb. 18.

Brief Summary: This is a retrospective, non interventional cohort study using stored plasma samples from appoximately 500 adults hospitalized with confirmed COVID 19. Baseline suPAR measured using the suPARnostic TurbiLatex assay on the Roche cobas c501.

Study Start Date: Feb. 01, 2020

Study Type: OBSERVATIONAL

Condition: COVID-19 Severe Respiratory Distress Syndrome Acute Respiratory Distress Syndrome

Intervention: DIAGNOSTIC_TEST: suPARnostic(R) TurbiLatex Assay on Roche cobas c501

Quantitative measurement of soluble urokinase plasminogen activator receptor (suPAR...